SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

A sharp broad-market selloff has focused attention on fears that the midterm results could bring tighter AI rules and slow data-center investment, weighing on technology and semiconductor stocks. Traders are debating whether the decline is an election-driven overreaction or a sign of a deeper correction, with many expressing bearishness while others see a buying opportunity.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IRENs quarterly results are driving attention, with traders weighing strong AI-cloud growth and a larger backlog against the delayed timeline for its contracted revenue ramp, rising debt and remaining data-center funding needs. Bulls call the operating progress encouraging and anticipate a short squeeze, while bears see execution and financing risksand question whether the upbeat reaction can last amid pressure on AI infrastructure stocks.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is drawing attention after a sharp Nasdaq selloff, with traders linking pressure to fears that political pushback could slow AI data-center expansion and to broader doubts about the AI trades sustainability. The community is divided over whether election-related concerns drove the decline or amplified a broader correction, with some calling it an overreaction and buying the dip while others expect further losses.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is caught in a semiconductor and AI-stock selloff as traders fear tighter AI regulation and data-center restrictions could slow infrastructure spending and chip demand. The community is split between buyers citing Microns valuation and persistent memory demand, and bears warning that AI-growth expectations may be reset and the decline could continue.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

A sharp semiconductor and AI-stock selloff is being tied to fears that election-driven data-center restrictions could slow AI infrastructure spending, alongside broader market de-leveraging. Some traders see an overreaction and are buying the dip, while others warn that AI spending and demand may not justify past expectations.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

A sharp semiconductor and broader tech selloff, fueled by AI and data-center investment concerns alongside election uncertainty, has hammered SOXL, with its 3x leverage amplifying the decline. Traders are split between calling it a buying opportunity or capitulation and warning that forced selling and leverage could drive further losses.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

AAOIs sharp selloff follows quarterly results that beat on revenue and adjusted earnings but included revenue guidance below expectations and a warning that U.S. capacity expansion will take longer than planned. Traders are split between near-term guidance and execution concerns and the longer-term AI-optics demand and hyperscaler agreement.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings Q3 results missed expectations and its FY26 guidance was cut, with increased investment in Predictions weighing on the outlook. Traders are largely criticizing management and questioning profitability, while some see the selloff as a buying opportunity and expect football-season results or Predictions growth to help.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQs quarterly report beat expectations and raised its full-year revenue outlook, drawing attention despite a sharp share-price decline. Traders welcomed the growth and backlog, while others focused on dilution, cash burn, and whether acquisitions are driving durable revenue.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodatas Q3 results beat expectations and management raised its growth outlook, while confirming that a program at a large customer is winding down and expected to be replaced by new work. Traders largely welcomed the results and new customer programs, though some remain concerned about customer concentration and whether replacement contracts will offset the wind-down.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Alkermes (ALKS) Surpasses Q3 Earnings and Revenue Estimates

Alkermes (ALKS) delivered earnings and revenue surprises of +212.50% and +3.05%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Phathom Pharmaceuticals, Inc. (PHAT) Lags Q3 Earnings and Revenue Estimates

Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of -42.86% and -1.71%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

If You Invested $100 In Roivant Sciences Stock 5 Years Ago, You Would Have This Much Today

Roivant Sciences (NASDAQ:ROIV) has outperformed the market over the past 5 years by 26.86% on an annualized basis producing an average annual return of 37.68%. Currently, Roivant Sciences has a market capitalization ofread more...

Why Is Roivant Sciences Stock Surging Wednesday?

Roivant (ROIV) shares jump as Phase 3 CLARITY trials show brepocitinib effectively treats noninfectious uveitis & reduces steroid reliance.read more...

Stocks making the biggest moves midday: SpaceX, Meta Platforms, Super Micro Computer, Roivant Sciences & more

Here are some of the companies making headlines in midday trading...

From Rocket Launches to Cancer Research: 6 Corporate Developments Investors Can’t Ignore

Investors are confronting a market increasingly shaped by the infrastructure behind artificial intelligence, the commercialization of advanced technology, and the search for new medical treatments. NeOnc Technologies Holdings (NASDAQ:NTHI), Roivant Sciences (NASDAQ:ROIV), Robin Energy (NASDAQ:RBNE), SpaceX (NASDAQ:SPCX), Super Micro Computer (NASDAQ:SMCI), and Olenox Industries (NASDAQ:OLOX).

Here's How Much You Would Have Made Owning Roivant Sciences Stock In The Last 5 Years

Roivant Sciences (NASDAQ:ROIV) has outperformed the market over the past 5 years by 30.08% on an annualized basis producing an average annual return of 41.86%. Currently, Roivant Sciences has a market capitalization ofread more...

IMVT, ROIV Stocks Slide As Argenx Sjögren’s Trial Failure Hits Drug Class

Equity

Immunovant is developing IMVT-1402 in an ongoing mid-stage study in Sjögren’s disease, which works the same way as Argenx’s efgartigimod.


Roivant Sciences (NASDAQ:ROIV) has outperformed the market over the past 5 years by 27.07% on an annualized basis producing an average annual return of 39.09%. Currently, Roivant Sciences has a market capitalization ofread more...

Why Did DELL, ROIV, SHEL Stocks Surge To 52-Week Highs Today?

Investors rewarded three very different catalysts spanning artificial intelligence, biotechnology, and energy.


Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

Roivant Sciences Ltd

Neutral Sentiment

<ul class="summary-bullets"><li>IMVT-1402 missed its main goal in a cutaneous lupus study in September, and that program was dropped.</li><li>H.C. Wainwright termed Argenx’s trial halt in Sjögren’s a “surprising setback.”</li><li>Wainwright said it is now more cautious about what the failure implies for Immunovant’s mid-stage study.</li></ul><p>Shares of Immunovant (IMVT) sold off Thursday as traders treated Argenx’s (ARGX) failed late-stage Sjögren’s trial as a warning for its own experimental drug for the autoimmune disorder.</p><p>Immunovant (IMVT) fell about 6% to $30.06 in morning trading. Its parent Roivant (ROIV) was also weaker, trading down roughly 2%.</p><h2 class="st-heading-2">Why Did IMVT, ROIV Fall On Rival Trial?</h2><p>Immunovant is developing IMVT-1402 in an ongoing mid-stage study in Sjögren’s disease. Argenx’s efgartigimod works the same way: it lowers circulating IgG antibodies that can drive autoimmune disease.</p><p>A late-stage failure for a closely related drug raises the odds that simply reducing IgG may not be enough in Sjögren’s. The move also follows Immunovant’s late-September setback, when IMVT-1402 missed its main goal in a cutaneous lupus study, and that program was dropped.</p><p>Roivant is the majority owner of Immunovant, and IMVT-1402 is central to the group’s autoimmune story.</p><h2 class="st-heading-2">ARGX’s Failed Trial</h2><p>Argenx has stopped its late-stage UNITY study of weekly subcutaneous efgartigimod in adults with moderate-to-severe Sjögren’s disease. An independent monitoring committee, after an interim look, said the trial was unlikely to meet its main goal: a reduction in systemic disease activity at week 48, the company said. Safety matched the drug’s known profile, with no new signals.</p><p>Sjögren’s, which causes dry eyes, dry mouth, fatigue and joint pain, still has no approved targeted therapy and is unusually varied from patient to patient, which makes trials hard to win.</p><p>Argenx’s U.S. shares were down about 14% to $797.69. The drug is already approved as Vyvgart for the treatment of generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy (CIDP). The failed trial removes the Sjögren’s path for Vyvgart.</p><h2 class="st-heading-2">Analyst Weighs In On ARGX’s Failed Trial</h2><p>H.C. Wainwright analyst Douglas Tsao called it a good-news, bad-news day for Argenx. On the positive side, the analyst said a 126-patient mid-stage study of FB102 in celiac disease met its primary endpoint. Argenx acquired FB102 through its $2.2 billion acquisition of Forte Biosciences. The firm sees that result as real validation of Argenx’s Forte deal and a clear step toward a late-stage study.</p><p>The UNITY stop, by contrast, was a “surprising setback,” the firm said. Wainwright said it is now more cautious about what the failure implies for Immunovant’s mid-stage Sjögren’s study of IMVT-1402. It kept a ‘Buy’ on Argenx and a $1,202 price target.</p><h2 class="st-heading-2">How Did IMVT, ROIV, ARGX Retail Traders React?</h2><p>On Stocktwits, retail sentiment around IMVT and ROIV was in 'neutral' and 'bearish' territory, respectively.</p><p>Sentiment around ARGX, however, jumped from 'bearish' to 'bullish' territory.</p><p><a class="mention" data-mention="$IMVT" data-symbol-id="IMVT" href="https://stocktwits.com/symbol/IMVT" target="_blank">IMVT stock</a> has gained 19% this year, while ROIV has gained 55%. ARGX, however, has lost 4%.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/trump-reportedly-bought-up-to-25-m-in-meta-stock-the-largest-reported-purchase-among-517-transactions/cZDUoxfRBNw">Trump Reportedly Bought Up To $25M In Meta Stock, The Largest Reported Purchase Among 517 Transactions</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

Immunovant is developing IMVT-1402 in an ongoing mid-stage study in Sjögren’s disease, which works the same way as Argenx’s efgartigimod.

Argenx

Immunovant Inc

Fundamental investor

Technical trader

A mix of both

Fundamental analysis looks at earnings, valuation, and business quality, while technical analysis focuses on chart patterns, price action, and indicators, and many investors blend the two. How do you decide what to buy: fundamentals or technicals? Vote and explain your reasoning in the comments.

Current Price	$36.62
Prev Close	$38.23
Open	$38.23
Dividend Yield	0.00%
50-Day Moving Average	$36.67
Beta	0.93
Avg. Volume	6.42M
PE Ratio	-87.16

52-Week High	$42.50
52-Week Low	$19.79
Market Capitalization	$27.61B
EPS (Annual)	-$0.432
Price to Book	6.53
Revenue Per Employee	$11,456.31

Feed

News

Sentiment

Earnings

Fundamentals

Info

ROIV Fundamentals